Chloroquine-induced cardiomyopathy: a reversible cause of heart failure
- PMID: 29460476
- PMCID: PMC5933951
- DOI: 10.1002/ehf2.12276
Chloroquine-induced cardiomyopathy: a reversible cause of heart failure
Abstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-rheumatic medications frequently used in the treatment of connective tissue disorders. We present the case of a 45-year-old woman with CQ-induced cardiomyopathy leading to severe heart failure. Electrocardiographic abnormalities included bifascicular block, while structural disease consisted of severe biventricular and biatrial hypertrophy. Appropriate diagnosis via endomyocardial biopsy led to cessation of CQ and subsequent dramatic improvement in symptoms and structural heart disease. Cardiac toxicity is an under-recognized adverse effect of CQ/HCQ leading to cardiomyopathy with concentric hypertrophy and conduction abnormalities, with the potential for significant morbidity and mortality. Predisposing factors for CQ/HCQ-induced cardiomyopathy have been proposed. CQ/HCQ cardiomyopathy is a phenocopy of Fabry disease, and α-galactosidase A polymorphism may account for some heterogeneity of disease presentation.
Keywords: Cardiac MRI; Cardiomyopathy; Chloroquine; Heart failure.
© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Figures
Similar articles
-
Cardiomyopathy related to antimalarial therapy with illustrative case report.Cardiology. 2007;107(2):73-80. doi: 10.1159/000094079. Epub 2006 Jun 22. Cardiology. 2007. PMID: 16804295 Review.
-
Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.Am J Clin Pathol. 2021 May 18;155(6):793-801. doi: 10.1093/ajcp/aqaa253. Am J Clin Pathol. 2021. PMID: 33316045 Free PMC article. Review.
-
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI.JACC Cardiovasc Imaging. 2020 Mar;13(3):879-881. doi: 10.1016/j.jcmg.2019.09.014. Epub 2019 Nov 13. JACC Cardiovasc Imaging. 2020. PMID: 31734202 No abstract available.
-
Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.Can J Cardiol. 2014 Dec;30(12):1706-15. doi: 10.1016/j.cjca.2014.08.016. Epub 2014 Aug 23. Can J Cardiol. 2014. PMID: 25475472 Review.
-
Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.Br J Clin Pharmacol. 2021 Mar;87(3):1432-1442. doi: 10.1111/bcp.14546. Epub 2020 Sep 22. Br J Clin Pharmacol. 2021. PMID: 32964535
Cited by
-
The Role of α3β1 Integrin Modulation on Fabry Disease Podocyte Injury and Kidney Impairment.Toxins (Basel). 2023 Dec 14;15(12):700. doi: 10.3390/toxins15120700. Toxins (Basel). 2023. PMID: 38133204 Free PMC article.
-
Hydroxychloroquine in nephrology: current status and future directions.J Nephrol. 2023 Nov;36(8):2191-2208. doi: 10.1007/s40620-023-01733-6. Epub 2023 Aug 2. J Nephrol. 2023. PMID: 37530940 Free PMC article. Review.
-
Doxorubicin-induced acute cardiotoxicity is associated with increased oxidative stress, autophagy, and inflammation in a murine model.Naunyn Schmiedebergs Arch Pharmacol. 2023 Jun;396(6):1105-1115. doi: 10.1007/s00210-023-02382-z. Epub 2023 Jan 16. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36645429 Free PMC article.
-
Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.Curr Heart Fail Rep. 2022 Dec;19(6):458-466. doi: 10.1007/s11897-022-00581-y. Epub 2022 Sep 27. Curr Heart Fail Rep. 2022. PMID: 36167917 Free PMC article. Review.
-
A Peculiar Case of Fentanyl-Induced Cardiomyopathy.Cureus. 2022 Aug 5;14(8):e27708. doi: 10.7759/cureus.27708. eCollection 2022 Aug. Cureus. 2022. PMID: 36081981 Free PMC article.
References
-
- Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J. Drugs that may cause or exacerbate heart failure. Circulation 2016; 134: e32‐e69. - PubMed
-
- Eschenhagen T, Force T, Ewer MS, Keulenaer GW, Suter TM, Anker SD, Avkiran M, Azambuja E, Balligand JL, Brutsaert DL. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 1–10. - PubMed
-
- Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, Oudit GY. Hydroxychloroquine‐induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol 2014; 30: 1706–1715. - PubMed
-
- Ferrari R, Böhm M, Cleland JG, Paulus WJ, Pieske B, Rapezzi C, Tavazzi L. Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 2015; 17: 665–671. - PubMed
-
- Tselios K, Gladman DD, Harvey P, Mak S, Chantal M, Butany J, Urowitz MB. Hydroxychloroquine‐induced cardiomyopathy in systemic lupus erythematosus. J Clin Rheumatol: Practical Reports on Rheumatic & Musculoskeletal Diseases 2016; 22: 287–288. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
